Application progress of liquid biopsy in the diagnosis and treatment of gastrointestinal tumors

doi:10.3877/cma.j.issn.2095-3224.2022.02.002

Abstract

Abstract:

As an emerging non-invasive detection technology, liquid biopsy mainly includes the detection of biomarkers such as circulating tumor cells, circulating tumor DNA, microRNA, and exosomes. In recent years, tumors of the digestive system, represented by pancreatic cancer, colorectal cancer, and gastric cancer, have become a vital disease burden that threatens the health of the Chinese people, and most patients are diagnosed in the advanced stages. Therefore, how to improve the diagnosis and screening methods of digestive system tumors and prolong the survival period of patients should become the current research focus. This review discusses the status and prospects of the clinical application of liquid biopsy in the diagnosis and treatment of digestive system tumors.

Yu Jun. Application progress of liquid biopsy in the diagnosis and treatment of gastrointestinal tumors[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(02): 104-107.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2022.02.002

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2022/V11/I02/104

References 35

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a Cancer Journal For Clinicians, 2021, 71(3): 209-249.
[2]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
[3]	Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5): 297-312.
[4]	De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis[J]. Trends In Pharmacological Sciences, 2019, 40(3): 172-186.
[5]	杨延巍, 刘彦虹. 液体活检在常见肿瘤中的应用[J/CD]. 中华结直肠疾病电子杂志, 2017, 6(2): 135-138.
[6]	Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. The Medical Journal of Australia, 1869, 14: 146-147.
[7]	Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells[J]. Nature, 2016, 529(7586): 298-306.
[8]	Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis[J]. Developmental Cell, 2008, 14(6): 818-829.
[9]	Joosse SA, Pantel K. Tumor-educated platelets as liquid biopsy in cancer patients[J]. Cancer Cell, 2015, 28(5): 552-554.
[10]	Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood[J]. Nature Reviews. Clinical Oncology, 2013, 10(8): 472-484.
[11]	Joseph R. Habib JY. Circulating tumor cells in pancreatic cancer: a review[J]. Journal of Pancreatology, 2019(2): 54-59.
[12]	Kang HM, Kim GH, Jeon HK, et al. Circulating tumor cells detected by lab-on-a-disc: Role in early diagnosis of gastric cancer[J]. PloS One, 2017, 12(6): e0180251.
[13]	Kulemann B, Rösch S, Seifert S, et al. Pancreatic cancer: Circulating tumor cells and primary tumors show heterogeneous KRAS mutations[J]. Sci Rep, 2017, 7(1): 4510.
[14]	Poruk KE, Blackford AL, Weiss MJ, et al. Circulating tumor cells expressing markers of tumor-initiating cells predict poor survival and cancer recurrence in patients with pancreatic ductal adenocarcinoma[J]. Clinical Cancer Research: an Official Journal of the American Association For Cancer Research, 2017, 23(11): 2681-2690.
[15]	Okubo K, Uenosono Y, Arigami T, et al. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer[J]. European Journal of Surgical Oncology: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, 43(6): 1050-1055.
[16]	Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study[J]. Annals of Surgery, 2018, 268(3): 408-420.
[17]	Shen F, Zhu Y, Wang F, et al. Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer[J]. Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland, 2022, 24(1): 68-76.
[18]	Vivancos A, Aranda E, Benavides M, et al. Comparison of the clinical sensitivity of the idylla platform and the OncoBEAM RAS CRC assay for KRAS mutation detection in liquid biopsy samples[J]. Scientific Reports, 2019, 9(1): 8976.
[19]	László L, Kurilla A, Takács T, et al. Recent updates on the significance of KRAS mutations in colorectal cancer biology[J]. Cells, 2021, 10(3): 667.
[20]	张笑飞, 邹小明. EGFR／PI3K／Akt信号通路在结直肠癌中的研究进展[J/CD]. 中华结直肠疾病电子杂志, 2015, 4(3): 90-92.
[21]	Kalikaki A, Politaki H, Souglakos J, et al. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer[J]. PloS One, 2014, 9(8): e104902.
[22]	Toh JWT, Lim SH, Mackenzie S, et al. Association between microsatellite instability status and peri-operative release of circulating tumour cells in colorectal cancer[J]. Cells, 2020, 9(2): 425.
[23]	Joseph R. Habib LY, Jun Y. Pancreatic ductal adenocarcinoma: the role of circulating tumor DNA[J]. Journal of Pancreatology, 2019(2): 72-75.
[24]	Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer[J]. Nature, 2019, 570(7761): 385-389.
[25]	Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science (New York, N.Y.), 2018, 359(6378): 926-930.
[26]	Cohen JD, Javed AA, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J]. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(38): 10202-10207.
[27]	Luo H, Zhao Q, Wei W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer[J]. Sci Transl Med, 2020, 12(524): eaax7533.
[28]	Zill OA, Greene C, Sebisanovic D, et al. Cell-Free DNA next-generation sequencing in pancreatobiliary carcinomas[J]. Cancer Discovery, 2015, 5(10): 1040-1048.
[29]	Creemers A, Krausz S, Strijker M, et al. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis[J]. Biochimica Et Biophysica Acta. Reviews On Cancer, 2017, 1868(2): 394-403.
[30]	Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients[J]. Nature Medicine, 2015, 21(7): 795-801.
[31]	Ng SB, Chua C, Ng M, et al. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery[J]. Scientific Reports, 2017, 7: 40737.
[32]	Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance[J]. Molecular Cancer, 2019, 18(1): 75.
[33]	Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity[J]. Biochimica Et Biophysica Acta. Reviews On Cancer, 2019, 1871(2): 455-468.
[34]	Sorber L, Zwaenepoel K, Jacobs J, et al. Circulating cell-free DNA and RNA analysis as liquid biopsy: optimal centrifugation protocol[J]. Cancers, 2019, 11(4): 458.
[35]	Wu J, Hu S, Zhang L, et al. Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis[J]. Theranostics, 2020, 10(10): 4544-4556.

Please choose a citation manager

Content to export